α-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA‑138 expression

Wu,Jianbo; Wang,Li; Du,Xinhui; Sun,Qianqian; Wang,Yuanyuan; Li,Min; Zang,Wenqiao; Liu,Kangdong; Zhao,Guoqiang

doi:10.3892/or.2018.6187

α-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA‑138 expression

Authors:
- Jianbo Wu
- Li Wang
- Xinhui Du
- Qianqian Sun
- Yuanyuan Wang
- Min Li
- Wenqiao Zang
- Kangdong Liu
- Guoqiang Zhao
View Affiliations

Affiliations: School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: January 4, 2018 https://doi.org/10.3892/or.2018.6187
Pages: 1163-1172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer is a common malignant tumor worldwide. Inherent and acquired drug resistance are the major challenges faced in anticancer chemotherapy. This study aimed to explore the effects of α-solanine in regards to the chemosensitivity of esophageal cancer cells. We found that α-solanine enhanced the sensitivity of EC9706 and KYSE30 cells to 5-flurouracil (5-FU) and cisplatin (Cis) by promoting drug-induced apoptosis. qRT-PCR and western blotting results showed that α-solanine treatment promoted miR-138 expression and decreased survivin expression in EC9706 and KYSE30 cells. α-solanine also enhanced the inhibitory effects of 5-Fu and Cis in EC9706 transplanted tumors in mouse models. Dual-Luciferase reporter assay results confirmed survivin as the direct target gene of miR-138. MiR-138 inhibited survivin expression in EC9706 and KYSE30 cells. And miR-138 mimic and si-survivin had similar effects with α-solanine in suppressing survivin expression and promoting cancer cell death. miR-138 inhibitor reversed the chemosensitivity-enhancing effect of α-solanine. In EC9706 and KYSE30 cells, survivin overexpression rescued the cancer cells from apoptosis caused by α-solanine and miR-138 mimic expression. From these findings, we conclude that α-solanine enhanced the chemosensitivity of esophageal cancer cells to chemotherapy via the miR-138/survivin pathway. This study provides insight into the molecular mechanism underlying the chemosensitivity-enhancing function of α-solanine and suggests a new chemotherapeutic strategy for esophageal cancer treatment.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Rustgi AK and El-Serag HB: Esophageal carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
3	He SM, Li R, Kanwar JR and Zhou SF: Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem. 18:439–481. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
5	Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI
6	Rathore R, McCallum JE, Varghese E, Florea AM and Büsselberg D: Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis. 22:898–919. 2017. View Article : Google Scholar : PubMed/NCBI
7	Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy. Expert Opin Ther Targets. 12:463–476. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ye Q, Cai W, Zheng Y, Evers BM and She QB: ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 33:1828–1839. 2014. View Article : Google Scholar : PubMed/NCBI
9	Glienke W, Maute L, Wicht J and Bergmann L: The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 33:757–765. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, et al: Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 17:597–604. 2006. View Article : Google Scholar : PubMed/NCBI
11	Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto G, et al: Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 119:1717–1722. 2006. View Article : Google Scholar : PubMed/NCBI
12	Singh N, Krishnakumar S, Kanwar RK, Cheung CH and Kanwar JR: Clinical aspects for survivin: A crucial molecule for targeting drug-resistant cancers. Drug Discov Today. 20:578–587. 2015. View Article : Google Scholar : PubMed/NCBI
13	Qian Y, Ma J, Guo X, Sun J, Yu Y, Cao B, Zhang L, Ding X, Huang J and Shao JF: Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation. Cell Physiol Biochem. 35:1381–1393. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhang SX, Qiu QH, Chen WB, Liang CH and Huang B: Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma. Cell Physiol Biochem. 33:1484–1497. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang BF, Wang XJ, Kang HF, Bai MH, Guan HT, Wang ZW, Zan Y, Song LQ, Min WL, Lin S, et al: Saikosaponin-D enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1α. Cell Physiol Biochem. 33:37–51. 2014. View Article : Google Scholar : PubMed/NCBI
16	Punjabi S, Cook LJ, Kersey P, Marks R and Cerio R: Solasodine glycoalkaloids: A novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol. 47:78–82. 2008. View Article : Google Scholar : PubMed/NCBI
17	Friedman M, Lee KR, Kim HJ, Lee IS and Kozukue N: Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells. J Agric Food Chem. 53:6162–6169. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lee KR, Kozukue N, Han JS, Park JH, Chang EY, Baek EJ, Chang JS and Friedman M: Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J Agric Food Chem. 52:2832–2839. 2004. View Article : Google Scholar : PubMed/NCBI
19	Lv C, Kong H, Dong G, Liu L, Tong K, Sun H, Chen B, Zhang C and Zhou M: Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. PLoS One. 9:e878682014. View Article : Google Scholar : PubMed/NCBI
20	Mohsenikia M, Alizadeh AM, Khodayari S, Khodayari H, Kouhpayeh SA, Karimi A, Zamani M, Azizian S and Mohagheghi MA: The protective and therapeutic effects of alpha-solanine on mice breast cancer. Eur J Pharmacol. 718:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Wu J, Guo W, Sun Q, Chen X, Zang W, Dong Z and Zhao G: α-solanine modulates the radiosensitivity of esophageal cancer cells by inducing microRNA 138 expression. Cell Physiol Biochem. 39:996–1010. 2016. View Article : Google Scholar : PubMed/NCBI
22	van Sleen Y, Wang Q, van der Geest KSM, Westra J, Abdulahad WH, Heeringa P, Boots AMH and Brouwer E: Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis. Sci Rep. 7:65532017. View Article : Google Scholar : PubMed/NCBI
23	Meng XQ, Zhang W, Zhang F, Yin SY, Xie HY, Zhou L and Zheng SS: Solanine-induced reactive oxygen species inhibit the growth of human hepatocellular carcinoma HepG2 cells. Oncol Lett. 11:2145–2151. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wen Z, Huang C, Xu Y, Xiao Y, Tang L, Dai J, Sun H, Chen B and Zhou M: α-solanine inhibits vascular endothelial growth factor expression by down-regulating the ERK1/2-HIF-1α and STAT3 signaling pathways. Eur J Pharmacol. 771:93–98. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhang F, Yang R, Zhang G, Cheng R, Bai Y, Zhao H, Lu X, Li H, Chen S, Li J, et al: Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression. Tumour Biol. 37:6437–6446. 2016. View Article : Google Scholar : PubMed/NCBI
26	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
27	Zhu Z, Tang J, Wang J, Duan G, Zhou L and Zhou X: miR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
28	Jiang B, Mu W, Wang J, Lu J, Jiang S, Li L, Xu H and Tian H: MicroRNA-138 functions as a tumor suppressor in osteosarcoma by targeting differentiated embryonic chondrocyte gene 2. J Exp Clin Cancer Res. 35:692016. View Article : Google Scholar : PubMed/NCBI
29	Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF and Zhang XY: miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar : PubMed/NCBI
30	Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q and Li L: MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother. 77:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
31	Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, Dai Y and Zhou X: MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J. 440:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhao X, Yang L, Hu J and Ruan J: miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res. 34:1078–1082. 2010. View Article : Google Scholar : PubMed/NCBI
33	Wang Q, Zhong M, Liu W, Li J, Huang J and Zheng L: Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res. 37:427–434. 2011. View Article : Google Scholar : PubMed/NCBI
34	Du J, Kelly AE, Funabiki H and Patel DJ: Structural basis for recognition of H3T3ph and Smac/DIABLO N-terminal peptides by human Survivin. Structure. 20:185–195. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H and Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res. 82:607–611. 2003. View Article : Google Scholar : PubMed/NCBI
36	Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S and Cheung CH: Treat cancers by targeting survivin: Just a dream or future reality? Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar : PubMed/NCBI